Adaptive chest radiation for newly diagnosed small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a customized (“adaptive”) way to give radiation to the chest for newly diagnosed small cell lung cancer. It aims to improve how well treatment targets the tumor while safely adjusting to tumor changes during therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and newly diagnosed with small cell lung cancer (SCLC) from a biopsy
- Have had standard scans (CT chest/abdomen/pelvis, plus a bone scan and/or PET-CT; and CT head or MRI brain)
- Be eligible for the usual chemotherapy combination called a “platinum doublet”
- Have lung function tests showing FEV-1 over 1.0 liter and DLCO over 50% of predicted
- Have chest disease that radiation can target, including some lymph nodes near the collarbone (supraclavicular)
- Agree to follow study rules, including treatment and follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether giving additional targeted radiation to the chest can help people with extensive-stage small cell lung cancer after they finish standard chemo-immunotherapy. It may help control the cancer in the lung area and prevent it from coming back there.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
This study tests using a shorter course of radiation (hypofractionated radiotherapy) combined with immunotherapy for people with limited-stage small-cell lung cancer. The goal is to see if this approach works better at controlling the cancer and may cause fewer side effects.
This trial tests a combination of chemotherapy, immunotherapy, and a special type of radiation given in split sessions for people with extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better.
This trial tests a chemotherapy drug called nab-paclitaxel combined with other local treatments (like radiation) for people with small cell lung cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer and improves outcomes.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.